Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)
China · Delayed Price · Currency is CNY 32.72
+2.58 (8.56%)
Feb 4, 2026, 3:04 PM CST
SHE:300683 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 616.61 | 645.7 | 594.48 | 680.74 | 608.2 | 517.97 |
Other Revenue | 3.27 | 3.27 | 7.8 | 7.89 | 6.49 | 6.16 |
| 619.88 | 648.97 | 602.28 | 688.63 | 614.68 | 524.12 | |
Revenue Growth (YoY) | 0.82% | 7.75% | -12.54% | 12.03% | 17.28% | -15.49% |
Cost of Revenue | 379.4 | 380.88 | 369.73 | 358.87 | 264.86 | 215.42 |
Gross Profit | 240.48 | 268.09 | 232.56 | 329.75 | 349.82 | 308.7 |
Selling, General & Admin | 249.27 | 245.86 | 241.99 | 220.52 | 242.96 | 242.89 |
Research & Development | 99.04 | 121.75 | 128.9 | 121.43 | 103.17 | 86.12 |
Other Operating Expenses | 21.89 | 7.11 | 5.44 | 5.64 | 3.51 | 3.06 |
Operating Expenses | 379.61 | 384.17 | 372.1 | 363.44 | 363.02 | 343.87 |
Operating Income | -139.13 | -116.08 | -139.54 | -33.69 | -13.2 | -35.17 |
Interest Expense | -1.32 | -2.3 | -2.39 | -1.12 | -0.5 | -0.46 |
Interest & Investment Income | 29.47 | 24.84 | 25.68 | 23.9 | 27.94 | 40.33 |
Other Non Operating Income (Expenses) | -1.3 | -0.71 | -0.46 | -0.49 | -0.56 | -0.56 |
EBT Excluding Unusual Items | -112.28 | -94.24 | -116.71 | -11.4 | 13.68 | 4.13 |
Impairment of Goodwill | - | - | -38.56 | -14.02 | - | -11.81 |
Gain (Loss) on Sale of Investments | -7.64 | -10.22 | 1.9 | 12.67 | -0.33 | -31.84 |
Gain (Loss) on Sale of Assets | -1.03 | -0.07 | -0.36 | -0.09 | -0.18 | -0.09 |
Asset Writedown | -105.06 | -1.15 | -4.03 | -0.06 | -0.02 | -2.8 |
Other Unusual Items | 25.54 | 25.54 | 5.78 | 5.07 | 7.31 | 5.04 |
Pretax Income | -200.47 | -80.14 | -151.99 | -7.82 | 20.46 | -37.37 |
Income Tax Expense | -8.02 | -6.37 | -23.74 | 0.07 | -9.56 | -11.69 |
Earnings From Continuing Operations | -192.45 | -73.77 | -128.24 | -7.9 | 30.01 | -25.67 |
Minority Interest in Earnings | 4.76 | 4.42 | 7.42 | -6.13 | -2.36 | 0.65 |
Net Income | -187.7 | -69.35 | -120.82 | -14.03 | 27.65 | -25.03 |
Net Income to Common | -187.7 | -69.35 | -120.82 | -14.03 | 27.65 | -25.03 |
Shares Outstanding (Basic) | 129 | 131 | 130 | 128 | 106 | 104 |
Shares Outstanding (Diluted) | 129 | 131 | 130 | 128 | 106 | 104 |
Shares Change (YoY) | -3.98% | 0.71% | 1.86% | 19.91% | 2.00% | 0.91% |
EPS (Basic) | -1.45 | -0.53 | -0.93 | -0.11 | 0.26 | -0.24 |
EPS (Diluted) | -1.45 | -0.53 | -0.93 | -0.11 | 0.26 | -0.24 |
Free Cash Flow | -142.29 | -20.39 | -162.13 | -120.94 | -235.02 | -133.33 |
Free Cash Flow Per Share | -1.10 | -0.16 | -1.25 | -0.95 | -2.21 | -1.28 |
Dividend Per Share | - | 0.130 | - | - | - | - |
Gross Margin | 38.80% | 41.31% | 38.61% | 47.88% | 56.91% | 58.90% |
Operating Margin | -22.45% | -17.89% | -23.17% | -4.89% | -2.15% | -6.71% |
Profit Margin | -30.28% | -10.69% | -20.06% | -2.04% | 4.50% | -4.78% |
Free Cash Flow Margin | -22.96% | -3.14% | -26.92% | -17.56% | -38.23% | -25.44% |
EBITDA | -38.61 | -29.2 | -70.85 | 17.5 | 22.42 | -6.18 |
EBITDA Margin | -6.23% | -4.50% | -11.76% | 2.54% | 3.65% | -1.18% |
D&A For EBITDA | 100.52 | 86.88 | 68.69 | 51.18 | 35.62 | 28.99 |
EBIT | -139.13 | -116.08 | -139.54 | -33.69 | -13.2 | -35.17 |
EBIT Margin | -22.44% | -17.89% | -23.17% | -4.89% | -2.15% | -6.71% |
Revenue as Reported | 619.88 | 648.97 | 602.28 | 688.63 | 614.68 | 524.12 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.